Ameet Mallik
Chief Executive Officer
Bio
Ameet Mallik
Chief Executive Officer
Ameet Mallik joined ADC Therapeutics in May 2022 and has over 25 years of industry experience. Before joining ADC Therapeutics, he served as CEO of Rafael Holdings, a novel cancer and immune metabolism therapeutics company.
Prior to Rafael Holdings, Mr. Mallik spent more than 16 years at Novartis where he served as Executive Vice President and Head, U.S. Oncology from November 2017 through April 2021. Prior to this position, Mr. Mallik served Novartis Oncology as Global Head, Marketing, Value and Access, and Head, Latin America and Canada. Mr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial and leadership roles at Novartis and Sandoz. At Sandoz, Mr. Mallik was Global Head of Biopharmaceuticals & Oncology Injectables. Before working in pharma, Mr. Mallik was an Associate Principal at McKinsey & Company. He currently serves on the Boards of Directors of ADC Therapeutics and Atara Biotherapeutics and is a Business Advisor for Juvena Therapeutics. In addition, he serves as Chair of the Board of Trustees for NJ LEEP.
Mr. Mallik holds an MBA from the Wharton School at the University of Pennsylvania and an MS in Biotechnology and BS in Chemical Engineering, both from Northwestern University.
Jose Carmona
Chief Financial Officer
Bio
Jose Carmona
Chief Financial Officer
Jose “Pepe” Carmona joined ADC Therapeutics as Chief Financial Officer in December 2022 bringing over 20 years of financial experience in the biotechnology and pharmaceutical industries.
Prior to ADC Therapeutics, Mr. Carmona was the CFO at Rubius Therapeutics, a biopharmaceutical company engineering red blood cells to create a new class of cellular medicines for cancer and autoimmune diseases. Before joining Rubius Therapeutics, he was the CFO of Radius Health, a global commercial company specializing in bone health. Prior to Radius Health, he served as CFO of Innocoll Holdings PLC, acquired by Gurnet Point L.P. Previously, Mr. Carmona spent 12 years at Novartis AG in numerous global and regional financial management positions across the business, including serving as CFO for divisions in Europe, North America and Latin America. He serves on the board of directors at Senda Biosciences and Hotspot Therapeutics.
Mr. Carmona holds an MBA from the Columbia Business School and received his BS in Civil Engineering from Universidad Tecnica Federico Santa Maria in Valparaiso, Chile.
Mohamed Zaki, MD, PhD
Chief Medical Officer
Bio
Mohamed Zaki, MD, PhD
Chief Medical Officer
Mohamed Zaki, MD, PhD joined ADC Therapeutics in January 2023 bringing over 20 years of global biopharmaceutical experience in hematology and oncology drug development.
Dr. Zaki joined ADC Therapeutics from Abbvie where he spent the last four years, most recently as Vice President and Global Head of Oncology Development. Prior to Abbvie, he spent nine years at Celgene in increasingly senior roles in oncology and hematology development. Previously, Dr. Zaki worked in clinical development at Sanofi-Aventis and Centocor Inc., a subsidiary of Johnson & Johnson.
Dr. Zaki earned his MD and MS at Ain Shams University School of Medicine in Cairo, Egypt and his PhD from the University of Pennsylvania and Ain Shams University School of Medicine in a joint degree program. He also served on the faculty of both institutions and was a practicing physician earlier in his career.
Kristen Harrington-Smith
Chief Commercial Officer
Bio
Kristen Harrington-Smith
Chief Commercial Officer
Ms. Harrington-Smith joined ADC Therapeutics in November 2022 with over 20 years of experience in the pharmaceutical industry. Most recently, she served as Chief Commercial Officer at ImmunoGen.
Prior to joining ImmunoGen, Ms. Harrington-Smith held roles of increasing responsibility at Novartis Pharmaceuticals including US Commercial Head of Hematology, where she led the commercial teams responsible for a portfolio of therapies in both malignant and non-malignant hematologic diseases including acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, idiopathic thrombocytopenic purpura, sickle cell disease, and paroxysmal nocturnal hemoglobinuria. Prior to this role, she was responsible for the commercial launch of Kymriah®, the first CAR-T-cell therapy for the treatment of diffuse large B-cell lymphoma and pediatric acute lymphoblastic leukemia, building the management, sales, marketing, and market access teams. She currently serves on the board of directors of eFFECTOR Therapeutics.
Ms. Harrington-Smith received a BA from Williams College and an MBA from the Kenan-Flagler Business School at the University of North Carolina.
Patrick van Berkel, PhD
Chief Scientific Officer
Bio
Patrick van Berkel, PhD
Chief Scientific Officer
Dr. van Berkel has more than 20 years of experience in the biotech industry, specializing in the development of antibody-based therapeutics.
Prior to joining ADC Therapeutics, Dr. van Berkel spent more than 9 years with Genmab in various roles, including Vice President of Antibody Technology and Vice President of CMC R&D.
Dr. van Berkel has a chemistry degree from the University of Nijmegen, The Netherlands (1991) and did his thesis at the University of Leiden, The Netherlands (1998).
David Ege
Chief Technical Officer
Bio
David Ege
Chief Technical Officer
David Ege is the Chief Technical Officer of ADCT. He has more than 20 years of experience in the pharmaceutical industry, with a focus in biologics, vaccines and novel modalities.
Prior to joining ADCT Dr. Ege was CTO, head of Process Development, Quality and Supply at Seres Therapeutics since 2020. He began his career at Merck in 2003, serving in a variety of technical and leadership roles in R&D, manufacturing and supply chain, in the U.S. and Switzerland. From 2015-2019, Dr. Ege served as Executive Director of Vaccines & Biologics Manufacturing at Merck’s plant in Elkton, VA where he led bulk manufacturing operations for the Gardasil® and Gardasil9® cervical cancer vaccines, as well as adjuvants and Cancidas® – a broad-based anti-fungal medicine made by fermentation. He has contributed to the successful first-in-class licensure and launch of cervical cancer vaccines, Gardasil® (2006) and Gardasil9® (2014), the breakthrough cancer immunotherapy, Keytruda®.
He graduated summa cum laude from Princeton with a BSE in chemical engineering and earned his PhD in chemical engineering from the University of Pennsylvania.
Peter Graham
Chief Legal Officer
Bio
Peter Graham
Chief Legal Officer
Mr. Graham serves as Chief Legal Officer and has over 25 years of legal, compliance and executive management experience in publicly and privately held pharmaceutical and medical device companies.
Most recently, from 2015 until its sale to Halozyme Therapeutics, Inc. in 2022, Mr. Graham served as Executive Vice President, General Counsel, Chief Compliance Officer, Human Resources and Secretary for Antares Pharma, Inc., a commercial stage specialty pharmaceutical and combination product company. Prior to Antares, Mr. Graham served as Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources for Delcath Systems, Inc., an interventional oncology company focused on liver cancers. Earlier in his career, Mr. Graham served in various senior legal and executive leadership positions at ACIST Medical Systems, Inc., a subsidiary of Bracco, SpA, E-Z-EM, Inc. and AngioDynamics, Inc.
Mr. Graham earned his JD at Yeshiva University’s Benjamin N. Cardozo School of Law and his BA in Political Science at the University of Wisconsin-Madison.
Kimberly Pope
Chief People Officer
Bio
Kimberly Pope
Chief People Officer
Ms. Pope has more than 30 years of experience in Human Resources, with over 20 years in the pharmaceutical industry.
Most recently, Ms. Pope was the SVP of Human Resources at Array BioPharma where she helped to build and transform the organization in preparation for the first commercial product launch. Prior to her role at Array, Ms. Pope spent 2 ½ years at IDEX Corporation as a Group Vice President of HR and over 15 years at Hospira in a variety of human resources roles of increasing scope and responsibility.
Ms. Pope received her undergraduate degree in Marketing and Human Resources from the University of Iowa.
Board of Directors
Ron Squarer
Chairman
Bio
Ron Squarer
Chairman
Ron Squarer is a global biopharmaceutical leader with extensive oncology commercialization expertise.
Mr. Squarer served as Chief Executive Officer and a member of the Board of Directors of Array BioPharma, Inc. from 2012 until 2019, during which time he executed an oncology-focused research, development, and commercialization strategy that culminated in the successful commercial launches of Braftovi® (encorafenib) and Mektovi® (binimetinib). During his tenure at Array, the company’s market capitalization grew more than 30-fold, and the company was ultimately acquired by Pfizer Inc. at a total enterprise value of approximately $11.4 billion.
Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. As Senior Vice President and Chief Commercial Officer at Hospira, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, when it was sold to Hospira in 2007. Before serving as Senior Vice President, Global Corporate and Business Development at Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer (focused on oncology) and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the US and Europe.
Mr. Squarer currently serves as a member of the Board of Directors of Deciphera Pharmaceuticals, Inc. and Travere Therapeutics, Inc. He earned an MBA from the Kellogg School of Management, Northwestern University, and a Bachelor’s Degree in Biochemistry from the University of California, Berkeley.
Bob Azelby
Non-Executive Director
Bio
Bob Azelby
Non-Executive Director
Bob Azelby joined the Board of Directors in June 2023. Mr. Azelby is an experienced Chief Executive Officer and veteran board member who has spent over 30 years in the biopharmaceutical industry.
He served as President and Chief Executive Officer of Eliem Therapeutics, Inc., from October 2020 to February 2023. Prior to Eliem, he was the Chief Executive Officer of Alder Biopharmaceuticals, Inc., from June 2018 until it was acquired by H. Lundbeck in 2019. Before joining Alder BioPharmaceuticals, Mr. Azelby was the Chief Commercial Officer of Juno Therapeutics for three years until it was acquired by Celgene Corporation. Prior to Juno, he spent 15 years in commercial roles at Amgen, Inc.
Mr. Azelby serves on the boards of directors of Clovis Oncology, Inc., and Chinook Therapeutics, Inc. Previously, he served on the boards of directors for Eliem Therapeutics, Alder BioPharmaceuticals, Cascadian Therapeutics, Inc., and Immunomedics, Inc. He holds a BA in Economics and Religious Studies from the University of Virginia and an MBA from Harvard Business School.
Jean-Pierre Bizzari
Non-Executive Director
Bio
Jean-Pierre Bizzari
Non-Executive Director
Jean-Pierre Bizzari, M.D. joined ADC Therapeutics as a Non-Executive Director of our board of directors in June 2022.
He is a member of the scientific advisory board of France’s National Cancer Institute and a board member of the European Organisation of Research and Treatment of Cancer. From 2008 to 2015, Dr. Bizzari served as Executive Vice President, Group Head of Clinical Development Oncology at Celgene Corporation. Prior to that, he held various senior clinical development positions at Sanofi S.A., Aventis and Rhône-Poulenc. In addition to our board of directors, Dr. Bizzari also serves as a member of the boards of directors of Halozyme Therapeutics, Inc., Oxford BioTherapeutics Limited, and Nordic Nanovector ASA, and previously served on the boards of directors of Transgene S.A., Onxeo SA and Compugen Limited. Dr. Bizzari holds an M.D. from Nice Medical School.
Tim Coughlin, CPA
Non-Executive Director
Bio
Tim Coughlin, CPA
Non-Executive Director
Timothy Coughlin, CPA, joined the Board of Directors in June 2025.
He is the former chief financial officer of Neurocrine Biosciences, Inc., a biopharmaceutical company that received FDA approval for INGREZZA® (valbenazine) and ORILISSA® (elagolix), both of which were discovered and developed during his tenure at Neurocrine from 2002 to 2018.
Mr. Coughlin currently serves on the board of directors of Travere Therapeutics, Inc., and as the chair of the board of directors of aTyr Pharma, Inc., both biotechnology companies. He previously served on the board of directors of Peloton Therapeutics, Inc. prior to its sale to Merck in 2019 and Fate Therapeutics, Inc. from 2013 to 2025, both biotechnology companies.
Prior to joining Neurocrine, he was with Catholic Health Initiatives, a nationwide integrated healthcare delivery system, where he served as vice president, Financial Services. Earlier in his career Mr. Coughlin served as a senior manager in the health sciences practice of Ernst & Young LLP and its predecessors.
Mr. Coughlin holds a master’s degree in international business from San Diego State University and a bachelor’s degree in accounting from Temple University. Mr. Coughlin is a certified public accountant in both California and Pennsylvania.
Peter Hug, PhD
Vice-Chairman and Lead Independent Director
Bio
Peter Hug, PhD
Vice-Chairman and Lead Independent Director
Dr. Peter Hug brings a wealth of global commercial and leadership experience to the Board of Directors of ADC Therapeutics.
Dr. Hug is a 35-year veteran of Roche, where he held positions of increasing responsibility until his retirement at the end of 2018. Most recently, he served as Head of Roche Pharma EEMEA Region, which comprises Eastern Europe, Russia, Central Asia, Turkey, the Middle East, and Africa. Previously, he was Head of Pharma Region Europe, during which time he led a successful transformation of its European commercial operations. Prior to that, Dr. Hug served as Executive Vice President of Roche Pharma Partnering, a role in which he was responsible for licensing, strategic alliances, and mergers and acquisitions. In earlier management roles within Roche, he was involved with multiple product launches, including hematology and oncology therapies.
Dr. Hug is a graduate of the University of Basel, Switzerland. He is also a Board Member and Vice Chairman of the Swiss Post, and he was President of Interpharma (Swiss Pharma Association) until the end of 2018.
Ameet Mallik
Chief Executive Officer
Bio
Ameet Mallik
Chief Executive Officer
Ameet Mallik joined ADC Therapeutics in May 2022 and has over 25 years of industry experience. Before joining ADC Therapeutics, he served as CEO of Rafael Holdings, a novel cancer and immune metabolism therapeutics company.
Prior to Rafael Holdings, Mr. Mallik spent more than 16 years at Novartis where he served as Executive Vice President and Head, U.S. Oncology from November 2017 through April 2021. Prior to this position, Mr. Mallik served Novartis Oncology as Global Head, Marketing, Value and Access, and Head, Latin America and Canada. Mr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial and leadership roles at Novartis and Sandoz. At Sandoz, Mr. Mallik was Global Head of Biopharmaceuticals & Oncology Injectables. Before working in pharma, Mr. Mallik was an Associate Principal at McKinsey & Company. He currently serves on the Boards of Directors of ADC Therapeutics and Atara Biotherapeutics and is a Business Advisor for Juvena Therapeutics. In addition, he serves as Chair of the Board of Trustees for NJ LEEP.
Mr. Mallik holds an MBA from the Wharton School at the University of Pennsylvania and an MS in Biotechnology and BS in Chemical Engineering, both from Northwestern University.
Viviane Monges
Non-Executive Director
Bio
Viviane Monges
Non-Executive Director
Viviane Monges is a Non-Executive Director on the Board of Directors of ADC Therapeutics.
Ms. Monges has more than 30 years of executive-level financial leadership experience with global corporations, predominantly in the pharmaceutical industry. From 2015 to 2017, she served as Chief Financial Officer (CFO) of the Business Excellence Division at Nestlé, S.A. Prior to that, Ms. Monges served as Group CFO at Galderma S.A; EMEA CFO and then Global CFO at the OTC Division of Novartis; CFO of the Europe Region unit and CFO of the Global Pharma Business unit at Wyeth Pharmaceuticals/Pfizer.
Ms. Monges also serves on the Board of Directors of DBV Technologies, Novo Holdings A/S, Voluntis S.A., and Union Chimique Belge Biopharmaceutical Company S.A. (UCB). She served on the board of Idorsia from 2018 to 2021. She holds a B.A. and an M.B.A. in finance and public administration from the École Supérieure de Commerce de Paris.
Tyrell J. Rivers, PhD
Non-Executive Director
Bio
Tyrell J. Rivers, PhD
Non-Executive Director
Tyrell J. Rivers, PhD, has served as a member of the Board of Directors of ADC Therapeutics since June 2018.
Dr. Rivers is also an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures, where he specialized in biotechnology investing, and at Merck & Co., Inc. where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development.
Dr. Rivers earned his BS in Chemical Engineering from the Massachusetts Institute of Technology, a PhD in Chemical Engineering from University of Texas at Austin, and his MBA from the New York University Stern School of Business. Dr. Rivers serves on the Board of Directors for Armaron Bio Ltd, Corvidia Therapeutics, PhaseBio Pharmaceuticals, Inc. and Viela Bio, Inc. and previously G1 Therapeutics, Inc. (GTHX). He also serves as a board observer for several private companies.
Victor Sandor, MD
Non-Executive Director
Bio
Victor Sandor, MD
Non-Executive Director
Victor Sandor, MD, is a Non-Executive Director on the Board of Directors of ADC Therapeutics.
Dr. Sandor was most recently Chief Medical Officer at Array BioPharma, Inc. prior to its acquisition by Pfizer Inc. At Array, Dr. Sandor was instrumental in obtaining the approval of Braftovi® (encorafenib) and Mektovi® (binimetinib). Prior to joining Array, he was Senior Vice President for Global Clinical Development at Incyte Corporation, where he played a critical role in the approval of Jakafi® (ruxolitinib). Dr. Sandor was also Vice President and Chief Medical Officer for Oncology at Biogen Idec and held positions of increasing responsibility in oncology product development at AstraZeneca, where he played an important role in the registration of Arimidex® (anastrozole) for adjuvant use and the development of several early-stage programs through proof of concept.
Dr. Sandor received his M.D.C.M. from McGill University in Montreal, Canada, and completed Fellowship in Medical Oncology at the National Institutes of Health.